ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the European launch of the company’s most advanced tissue valve — the Trifecta™ valve with Glide™ Technology (GT) — for the treatment of diseased, damaged or malfunctioning aortic heart valves, which control blood flow from the heart to the rest of the body. Tissue aortic valve replacement can improve quality of life for patients suffering heart failure or aortic regurgitation, ease symptoms and help patients live longer lives. For physicians, the new Trifecta™ GT tissue valve offers enhanced valve delivery to ease implantation in challenging anatomies and surgical approaches combined with the proven best-in-class hemodynamic excellence of the Trifecta™ valve.
The first Trifecta GT valve was implanted by Dr. Gebrine El Khoury, of St-Luc Hospital in Brussels, Belgium. Dr. El Khoury has extensive experience with the original Trifecta tissue valve and commented that the new Trifecta GT tissue valve, “will help us provide the best care possible for our patients in need of aortic valve replacement and especially those with challenging clinical cases.”
The new Trifecta GT valve builds on St. Jude Medical’s decades-long legacy of designing and developing mechanical and tissue heart valves for patients in need of options to replace their damaged or diseased native heart valves. The original Trifecta valve provided patients a tissue valve that was proven to function in the same way as their native aortic valve. Now, the Trifecta GT tissue valve has improved upon the original, and provides physicians a tissue valve option that is easier to implant but that retains its optimal hemodynamic (circulatory) performance.
“The excellent hemodynamic performance of the valve improves quality of life by restoring blood flow both at rest and during exercise, making it an outstanding choice for a wide range of patients,” said Pr. Alain Leguerrier, of Centre Hospitalier Universitaire de Rennes in Rennes, France. “The enhancements to the Trifecta GT tissue valve facilitate improved valve parachuting and seating, which means the valve can gently glide into place.”
Engineered to reduce wear and deterioration over time, the Trifecta GT valve stent is covered with tissue to allow improved tissue-to-tissue contact when the leaflets open and close. Additionally, the valve is treated with St. Jude Medical's Linx™ AC Treatment, an anticalcification treatment designed to reduce tissue mineralization (hardening). The valve’s fatigue-resistant titanium stent provides a supportive frame within a patient’s heart for added durability.
“For years, St. Jude Medical has dedicated significant resources to develop best-in-class heart valve replacement options while refining our devices based on physician feedback and clinical outcomes,” said Philip Ebeling, vice president and chief technology officer at St. Jude Medical. “The improved design of the Trifecta GT tissue valve allows for smoother placement while providing nearly unobstructed blood flow over the life of the valve. The Trifecta GT tissue valve is a true testament to our commitment to the cardiac surgery community and the patients they treat.”
The Trifecta GT tissue valve received CE Mark approval in February 2016, further expanding the St. Jude Medical valve product portfolio, which includes market-leading mechanical heart valves, aortic and mitral tissue valves, valve repair annuloplasty rings and the Portico™ TAVR valve available currently in Europe.
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management, and cardiovascular. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
